If you are not a HCP, please click here

Intended for UK Healthcare Professionals.

The prescribing information link and adverse event reporting statement are found at the bottom of this page.

Midazolam Protocol Resources
If you are not a HCP, please click here

Intended for UK Healthcare Professionals.
The prescribing information link and adverse event reporting statement are found at the bottom of this page.

Midazolam Protocol Resources
yellow-banner_2.png
slider-2.jpg
blue-banner_2-1.png
slider-3.jpg
purple-banner_2.png
slider-1.jpg
orange-banner_2.png
Seizures:
The Facts

Epistatus® in Paediatric Care

Epistatus® in Adult Care

Access

Resources

Epistatus® (midazolam maleate) is indicated for the treatment of prolonged, acute, convulsive seizures (PACS) in adults, adolescents, children and infants aged 3 months and above.

Epistatus® must only be used by parents / caregivers where the patient has been diagnosed to have epilepsy.1-4

Epistatus® 2.5 mg dose is contained in a volume of 0.25 mL1, 5 mg in 0.5 mL2, 7.5 mg in 0.75 mL3, and 10 mg in 1 mL4 Oromucosal Solution Midazolam (as maleate).

Patient Website

The role of Epistatus® as a rescue medication

Learn more about how Epistatus® helps manage breakthrough seizures in children and adults

Epistatus® administration

Watch an instructional video on how to prepare and administer Epistatus® and support post-seizure recovery
2.5 mg

For children aged 3-6 months

(in a hospital setting) and

>6 months to <1 year

the standard dose is

2.5 mg (0.25 mL)*1

5 mg

For children aged 1 year to less

than 5 years of age the

standard dose is

5 mg (0.5 mL)2

7.5 mg

For children aged 5 years to
less than 10 years of
age the standard dose
is 7.5 mg (0.75 mL)3

10 mg

For children, adolescents and
adults aged 10 years
and above the standard
dose is 10 mg (1 mL)4

*For infants between 3-6 months of age, treatment with the standard dose of 2.5 mg (0.25 mL) should be in a hospital setting, where monitoring is possible and resuscitation equipment is available1
References:
  1. Epistatus® 2.5 mg Oromucosal Solution Summary of Product Characteristics (SmPC).
  2. Epistatus® 5 mg Oromucosal Solution SmPC.
  3. Epistatus® 7.5 mg Oromucosal Solution SmPC.
  4. Epistatus® 10 mg Oromucosal Solution SmPC.

UK-EPI-2400072

Date of Preparation: October 2025

Request Training Resources